SCHEMBL517251

SCHEMBL517251

COC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(=O)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.40
DGAT1 O75907 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HDAC1 Q13547 4/20 0.36
HDAC7 Q8WUI4 4/20 0.36
HDAC8 Q9BY41 4/20 0.36
HDAC6 Q9UBN7 3/20 0.36
KCNN4 O15554 1/20 0.33
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC9 Q9UKV0 1/20 0.31
HDAC5 Q9UQL6 1/20 0.31
F2 P00734 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL672362 1.00 THRB (0.40) THRBDGAT1ALDH1A1HDAC1HDAC7
SCHEMBL3082673 1.00 THRB (0.40) THRBDGAT1ALDH1A1HDAC1HDAC7
SCHEMBL11205420 1.00 THRB (0.40) THRBDGAT1ALDH1A1HDAC1HDAC7
SCHEMBL497763 0.97 DGAT1 (0.39) THRBDGAT1ALDH1A1HDAC1HDAC7
SCHEMBL2691635 0.93 THRB (0.52) THRBDGAT1ALDH1A1HDAC1HDAC7
SCHEMBL674231 0.93 THRB (0.52) THRBDGAT1ALDH1A1HDAC1HDAC7
SCHEMBL516962 0.93 THRB (0.52) THRBDGAT1ALDH1A1HDAC1HDAC7
SCHEMBL198030 0.93 THRB (0.52) THRBDGAT1ALDH1A1HDAC1HDAC7
SCHEMBL517150 0.93 THRB (0.52) THRBDGAT1ALDH1A1HDAC1HDAC7
SCHEMBL497426 0.93 THRB (0.52) THRBDGAT1ALDH1A1HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012024592-A2 COMPOSITIONS, METHODS, AND SYSTEMS COMPRISING FLUOROUS-SOLUBLE POLYMERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-02-23 WO claimed
US-9156938-B2 Compositions, methods, and systems comprising fluorous-soluble polymers MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2015-10-13 US disclosed
US-8487003-B2 Modulation of plasma insulin, glucose, triglycerides, cholesterol and/or leptin using perfluorinated fatty acids CXR BIOSCIENCES LIMITED (GB) 2013-07-16 US disclosed
US-20120177578-A1 COMPOSITIONS, METHODS, AND SYSTEMS COMPRISING FLUOROUS-SOLUBLE POLYMERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-07-12 US disclosed
WO-2012024592-A2 COMPOSITIONS, METHODS, AND SYSTEMS COMPRISING FLUOROUS-SOLUBLE POLYMERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-02-23 WO disclosed
US-20120029079-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS CXR BIOSCIENCES LIMITED (GB) 2012-02-02 US disclosed
US-7955532-B2 High performance capsules for electrophoretic displays SIPIX IMAGING, INC. (US) 2011-06-07 US disclosed
EP-2260842-A2 Uses of perfluorinated carboylic acid derivatives for the manufacture of a medicament for the modulation of body mass CXR Biosciences Limited (GB) 2010-12-15 EP disclosed
EP-1359906-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS CXR BIOSCIENCES LTD (GB) 2008-05-14 EP disclosed
US-20070138675-A1 HIGH PERFORMANCE CAPSULES FOR ELECTROPHORETIC DISPLAYS E INK CALIFORNIA, LLC 2007-06-21 US disclosed
US-7184197-B2 High performance capsules for electrophoretic displays SIPIX IMAGING, INC. (US) 2007-02-27 US disclosed
EP-1745779-A2 Uses of perfluorinated carboylic acid derivatives for the manufacture of a medicament for the modulation of body mass CXR BIOSCIENCES LIMITED (GB) 2007-01-24 EP disclosed
US-20050175639-A1 Modulation of plasma insulin, glucose, triglycerides, cholesterol and/or leptin using perfluorinated fatty acids CXR BIOSCIENCES LIMITED (GB) 2005-08-11 US disclosed
US-20040182711-A1 Switching rate and resistance to humidity; allows low manufacturing cost because no drying, purification or re-dispersion of the capsules is needed to remove water or undesirable hydrophilic impurities E INK CORPORATION 2004-09-23 US disclosed
WO-2004068234-A1 HIGH PERFORMANCE CAPSULES FOR ELECTROPHORETIC DISPLAYS SIPIX IMAGING, INC. (US) 2004-08-12 WO disclosed
EP-1359906-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS CXR BIOSCIENCES LIMITED (GB) 2003-11-12 EP disclosed
CN-1455663-A Novel aerosol formulation containing polar fluorinated molecule ASTRAZENECA AB (SE) 2003-11-12 CN disclosed
WO-2002066028-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS CXR BIOSCIENCES LIMITED (GB) 2002-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120177578-A1 COMPOSITIONS, METHODS, AND SYSTEMS COMPRISING FLUOROUS-SOLUBLE POLYMERS NAF1, PFAS, MALT1 THRB 3638/4885DGAT1 609/4885ALDH1A1 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.